局部与全身炎症对经皮冠状动脉介入治疗后结局的预测价值
该前瞻性队列纳入1987例接受PCI的冠心病患者,评估冠周脂肪衰减指数(FAI)量化的局部炎症与高敏C反应蛋白(hs-CRP)反映的全身炎症对不良结局的预后价值。中位3年随访显示,高FAI-MAX与MACE和VOCE风险显著相关,局部炎症的关联强于全身炎症,双高表型风险最高,联合两者可改善风险分层。
要点
- 高FAI-MAX(≥-70 HU)与MACE(HR 3.25)和VOCE(HR 3.15)风险显著相关,关联强于hs-CRP。
- 高FAI-MAX合并高hs-CRP者风险最高(MACE HR 4.00;VOCE HR 4.15)。
- 局部高炎症而全身低炎症者的风险显著高于相反表型,联合两指标可改善模型区分度。
核心结论
- 局部冠状动脉炎症与PCI后不良结局的关联强于全身炎症。
- 联合局部与全身炎症标志物可改善风险分层,可能支持炎症指导的管理。
研究设计与样本
- 前瞻性队列研究,纳入1987例接受PCI的冠心病患者。
- 局部炎症用冠周脂肪衰减指数(FAI)量化,全身炎症用高敏C反应蛋白(hs-CRP)测量。
- 患者级主要终点为MACE(全因死亡、非致死性心肌梗死、非计划再次血运重建),血管级终点为VOCE。
主要发现
- 中位3年随访期间,164例患者(8.3%)发生MACE,2436支血管中118支(4.8%)发生VOCE。
- 极端梯度提升结合SHAP分析将FAI-MAX列为对MACE和VOCE最重要的局部炎症特征。
- 高FAI-MAX(≥-70 HU)与MACE(HR 3.25,95% CI 2.29-4.61)和VOCE(HR 3.15,95% CI 2.06-4.82)强相关。
- 高FAI-MAX且hs-CRP升高者风险最高(MACE HR 4.00,95% CI 2.47-6.32;VOCE HR 4.15,95% CI 2.37-7.25)。
- 局部高炎症伴全身低炎症者风险显著高于相反表型(MACE HR 2.88,95% CI 1.85-4.49 vs 1.09,95% CI 0.55-1.85;VOCE HR 2.64,95% CI 1.55-4.50 vs 1.08,95% CI 0.55-2.13)。
关键数值与推荐
- 高FAI-MAX定义为≥-70 HU。
- 高FAI-MAX与MACE的HR为3.25(95% CI 2.29-4.61),与VOCE的HR为3.15(95% CI 2.06-4.82)。
- 双高表型(高FAI-MAX且hs-CRP升高)与MACE的HR为4.00(95% CI 2.47-6.32),与VOCE的HR为4.15(95% CI 2.37-7.25)。
- 联合两标志物改善模型区分度的DeLong P < 0.05。
临床怎么用
- 对接受PCI的冠心病患者,可考虑评估冠周FAI和hs-CRP以进行炎症风险分层。
- 高FAI-MAX尤其合并hs-CRP升高者属高危,可能需要更密切随访或强化管理。
- 局部炎症标志物可能比全身炎症标志物提供更强的预后信息,支持炎症指导的管理决策。
局限性
- 排除血运重建的敏感性分析中,单纯高FAI-MAX的优势减弱,提示部分关联可能由血运重建驱动。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Inflammation influences outcomes after percutaneous coronary intervention (PCI) in coronary artery disease (CAD). This study aimed to evaluate the relative and combined prognostic value of local coronary inflammation, and systemic inflammation for adverse outcomes. METHODS: In a prospective cohort of 1,987 patients with CAD undergoing PCI, local inflammation, quantified by the pericoronary fat attenuation index (FAI), and systemic inflammation, measured by high-sensitivity C-reactive protein (hs-CRP), were assessed. The patient-level primary endpoint was major adverse cardiovascular events (MACE) including all-cause mortality, non-fatal myocardial infarction, and unplanned repeat revascularization. The vessel-level endpoint was the vessel-oriented composite endpoint (VOCE). RESULTS: Over a median 3-year follow-up, 164 patients (8.3%) experienced MACE and 118 of 2,436 vessels (4.8%) experienced VOCE. Extreme Gradient Boosting with SHAP analysis ranked FAI-MAX as the most important local inflammatory feature for both MACE and VOCE. High FAI-MAX (? -70 HU) was strongly associated with MACE (HR 3.25, 95% CI 2.29-4.61) and VOCE (HR 3.15, 95% CI 2.06-4.82). Patients with high FAI-MAX and elevated hs-CRP had the highest risk (MACE HR 4.00, 95% CI 2.47-6.32; VOCE HR 4.15, 95% CI 2.37-7.25). High local inflammation with low systemic inflammation conferred substantially greater risk than the converse phenotype (MACE HR 2.88, 95% CI 1.85-4.49 vs 1.09, 95% CI 0.55-1.85; VOCE HR 2.64, 95% CI 1.55-4.50 vs 1.08, 95% CI 0.55-2.13). Addition of both markers significantly improved model discrimination compared with either alone (DeLong P < 0.05). In sensitivity analysis excluding revascularization, the advantage of isolated high FAI-MAX was attenuated, while the dual-high phenotype remained significant. CONCLUSIONS: Local coronary inflammation shows a stronger association with adverse outcomes after PCI than systemic inflammation. Integrating both markers improves risk stratification and may support inflammation-guided management in patients with CAD.
引用
- Ye Z, Xie E, Liu C, et al. Local vs systemic inflammation and outcomes after percutaneous coronary intervention. Eur Heart J. 2026. PMID: 42667169. doi:10.1093/eurheartj/ehag731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。